1. Activity of Meropenem-Vaborbactam against Carbapenem-Resistant Enterobacteriaceae in a Murine Model of Pyelonephritis.
- Author
-
Weiss WJ, Pulse ME, Nguyen P, Peterson K, Silva J, Simecka JW, Valtierra D, Sabet M, and Griffith DC
- Subjects
- Animals, Bacterial Proteins metabolism, Carbapenem-Resistant Enterobacteriaceae isolation & purification, Disease Models, Animal, Drug Combinations, Humans, Klebsiella pneumoniae isolation & purification, Klebsiella pneumoniae metabolism, Mice, Microbial Sensitivity Tests, Pyelonephritis microbiology, Urinary Tract Infections microbiology, beta-Lactamases metabolism, Anti-Bacterial Agents therapeutic use, Boronic Acids therapeutic use, Carbapenem-Resistant Enterobacteriaceae drug effects, Escherichia coli drug effects, Klebsiella pneumoniae drug effects, Meropenem therapeutic use, Pyelonephritis drug therapy, Urinary Tract Infections drug therapy, beta-Lactamase Inhibitors therapeutic use
- Abstract
The recently approved combination of meropenem and vaborbactam (Vabomere) is highly active against Gram-negative pathogens, especially Klebsiella pneumoniae carbapenemase (KPC)-producing, carbapenem-resistant Enterobacteriaceae We evaluated the efficacy of meropenem-vaborbactam against three clinically relevant isolates in a murine pyelonephritis model. The data indicate that the combination of meropenem and vaborbactam significantly increased bacterial killing compared to that with the untreated controls. These data suggest that this combination may have utility in the treatment of complicated urinary tract infections due to KPC-producing, carbapenem-resistant Enterobacteriaceae ., (Copyright © 2017 American Society for Microbiology.)
- Published
- 2017
- Full Text
- View/download PDF